Search research articles
Contact Us
Filters
Showing results (111-120 of 120) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 120 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Annals of Hematology
|
March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
Annals of Hematology
|
October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Lida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
Swiss Medical Weekly
|
March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood
|
May 25, 2006
Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Rodrigo Martino, Rocio Parody, Takahiro Fukuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood
|
April 29, 2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV
Susanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, et al.
Cancers
|
February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Jeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Haematologica
|
December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Christian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 120) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 120 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Annals of Hematology
|
March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
Annals of Hematology
|
October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Lida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
Swiss Medical Weekly
|
March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood
|
May 25, 2006
Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Rodrigo Martino, Rocio Parody, Takahiro Fukuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood
|
April 29, 2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV
Susanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, et al.
Cancers
|
February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Jeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Haematologica
|
December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Christian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Page
of 12